This content is machine translated Chronic myeloid leukemia State of the Art – where are we at CML in 2017? CML patients have a normal life expectancy when treated with Abl-specific kinase inhibitors (TKIs) in chronic phase. Imatinib, dasatinib and nilotinib are approved in the first-line treatment of CML. In…
View Post 4 min This content is machine translated Chronic myeloid leukemia Diagnostics and therapy of CML – current state of knowledge A lot has happened in the field of chronic myeloid leukemia (CML) in recent years. Response and survival rates have risen sharply, and some patients are even said to be…
View Post 4 min This content is machine translated Onco-training in St. Gallen Targeted systems therapy in metastatic NSCLC. In more than half of all patients with lung cancer, metastases are already present at the time of diagnosis. In recent years, new compounds have been developed that can be…
View Post 4 min This content is machine translated Metastatic renal cell carcinoma. What are the reasons for resistance to current drugs? Practical strategies for treatment management of metastatic renal cell carcinoma (mRCC) were presented at the ESMO Congress in Amsterdam. Updates on current clinical trials and the utility of new treatment…
View Post 6 min This content is machine translated Tyrosine kinase inhibitors and the skin From common to rare side effects Epidermal-growth-factor receptors are found in the skin and sebaceous glands, tyrosine kinase (TK) in keratinizing skin, mucous membranes and hair, and are thus also targets of EGFR- and TK-inhibiting oncologics…
